Table 1.
End points at the conclusion of the two-month treatment phase [38].
| * End Point (units) | Placebo | P † | Allopurinol | P † | P Allopurinol vs. Placebo |
|---|---|---|---|---|---|
| Serum uric acid, mg/dL | 6.3 (5.8 to 6.8) | 4.1 (3.4 to 4.7) | |||
| (Change from baseline) | −0.3 (−0.1 to −0.7) | 0.048 | −2.8 (−2.1 to −3.6) | 0.0003 | 0.0005 |
| ‡ (Adjusted change) | −0.4 (−0.2 to −0.7) | 0.046 | −2.8 (−2.2 to −3.4) | 0.0003 | 0.0008 |
| SBP, mm Hg | 128.1 (124.8 to 131.4) | 118.1 (113.2 to 120.1) | |||
| (Change from baseline) | +1.7 (0.9 to 3.8) | 0.037 | −10.1 (−8.2 to −13.1) | 0.0002 | 0.0001 |
| (Adjusted change) | +1.0 (0.4 to 3.1) | 0.071 | −10.3 (−8.3 to −13.5) | 0.0002 | 0.0003 |
| DBP, mm Hg | 76.0 (73.6 to 78.4) | 66.2 (62.7 to 70.7) | |||
| (Change from baseline) | +1.6 (0.2 to 3.5) | 0.033 | −8.0 (−5.8 to −10.1) | 0.0006 | 0.0002 |
| (Adjusted change) | +1.3 (0.2 to 3.0) | 0.057 | −8.0 (−5.4 to −10.7) | 0.0006 | 0.0007 |
| 24-h SBP, mm Hg | 120.0 (114.9to125.1) | 113.5 (110.3 to 117.3) | |||
| (Change from baseline) | +1.9 (−0.4 to 2.4) | 0.310 | −9.2 (−6.7 to −11.3) | 0.0004 | 0.0008 |
| (Adjusted change) | +1.1 (−0.8 to 2.1) | 0.382 | −9.5 (−6.8 to −11.9) | 0.0003 | 0.0008 |
| 24-h DBP, mm Hg | 68.7 (66.4 to 71.1) | 0.262 | 62.4 (60.4 to 64.5) | ||
| (Change from baseline) | +1.3 (0.2 to 3.5) | 0.262 | −6.1 (−4.6 to −9.0) | 0.0009 | 0.0011 |
| (Adjusted change) | +0.9 (0.0 to 3.3) | 0.322 | −6.4 (−4.7 to −9.5) | 0.0007 | 0.0014 |
| Weight, kg | 99.8 (87.6 to 109.2) | 98.1 (81.2 to 110.4) | |||
| (Change from baseline) | +2.1 (1.7 to 2.8) | 0.008 | −0.9 (−1.5 to −0.6) | ||
| (Adjusted change) | N/A | N/A | 0.42 | 0.039 | |
| BMI, kg/m2 | 36.6 (32.3 to 39.9) | 36.1 (33.5–41.0) | |||
| (Change from baseline) | +0.9 (0 to +1.2) | 0.060 | −0.2 (−0.5 to +0.7) | 0.61 | 0.041 |
| (Adjusted change) | N/A | N/A | |||
| SVRi** (dyne s/cm5)/m2 | 2271 (2017 to 2527) | 1761 (1175 to 1946) | |||
| (Change from baseline) | +8.6% (−0.2% to 12.2%) | 0.145 | −24.5% (−49.6% to −16.5%) | 0.0006 | 0.0004 |
| (Adjusted change) | +2.3% (−0.8% to 5.1%) | 0.344 | −25.1% (−49.8% to −16.1%) | 0.0006 | 0.0003 |
BMI, body mass index; DBP, diastolic blood pressure; SBP, systolic blood pressure; SVRi, systemic vascular resistance index; N/A, not applicable. Parentheses delineate the 95% CI. * End points are the mean value the end of the treatment. † p-values are two- tailed t-test comparison of the mean change from pretreatment value. ‡ Values were adjusted for weight and BMI.